Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq ...
As of April 8, 2026, analyst sentiment toward Exagen Inc. (NASDAQ:XGN) remains bullish, with over 80% of covering analysts maintaining ‘Buy’ ratings on the stock. The consensus price target of $10 ...
Exagen Inc. (XGN) shares soared 29.4% in the last trading session to close at $5.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...
Shares of Exagen Inc. (XGN) have been struggling lately and have lost 5.9% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock ...
Zacks Investment Research on MSN
How much upside is left in Exagen (XGN)? Wall Street analysts think 73.05%
Shares of Exagen Inc. (XGN) have gained 81.5% over the past four weeks to close the last trading session at $5.01, but there ...
Fintel reports that Lytton Laurence W has filed a 13G/A form with the SEC disclosing ownership of 0.87MM shares of Exagen Inc (XGN). This represents 5.3% of the company. In their previous filing dated ...
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts
A week ago, Exagen Inc. (NASDAQ:XGN) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Results overall were solid, with revenues arriving 5.5% ...
) has been revised to $10.03 / share. This is a decrease of 21.78% from the prior estimate of $12.82 dated February 21, 2026. The price target is an average of many targets provided by analysts. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results